T he 8;21 translocation, t(8;21)(q22;q22), is one of the most frequent chromosomal abnormalities in acute myelogenous leukemia (AML) (1). It involves AML1 at 21q22 and ETO at 8q22, resulting in the expression of AML1͞ETO chimeric transcripts in leukemic cells (2-4). Recent studies have shown, using sensitive reverse transcriptase-PCR (RT-PCR) assays that AML1͞ETO transcripts remain detectable in most t(8;21) AML patients who maintain hematological and cytogenetic long-term remission after chemotherapy, autologous bone marrow (BM) transplantation, or autologous mobilized blood transplantation (MBT) (5-10).
T he 8;21 translocation, t(8;21)(q22;q22), is one of the most frequent chromosomal abnormalities in acute myelogenous leukemia (AML) (1) . It involves AML1 at 21q22 and ETO at 8q22, resulting in the expression of AML1͞ETO chimeric transcripts in leukemic cells (2) (3) (4) . Recent studies have shown, using sensitive reverse transcriptase-PCR (RT-PCR) assays that AML1͞ETO transcripts remain detectable in most t(8;21) AML patients who maintain hematological and cytogenetic long-term remission after chemotherapy, autologous bone marrow (BM) transplantation, or autologous mobilized blood transplantation (MBT) (5) (6) (7) (8) (9) (10) .
It remains unclear whether or not the persistence of AML1͞ETO in remission indicates minimal residual disease that may cause relapse. To understand this issue, one needs to know whether only malignant cells express AML1͞ETO, and what the function of these transcripts in AML1͞ETO-expressing cells is during remission. The long-term persistence of AML1͞ETO expression suggests that at least a subset of the cells with t(8;21) in remission would be capable of self-renewal; in normal marrow, this is a property largely restricted to hematopoietic stem cells (HSC). We have reported that AML1͞ETO transcripts could be found in a small fraction of myeloid progenitors in t(8;21) AML remission marrow, including burst-forming unit-erythroid (BFU-E), colonyforming unit-megakaryocytes (CFU-Meg), and CFU-granulocyte͞macrophages (CFU-GM) (10) . This finding raises an interesting possibility that t(8;21) might involve HSC and their descendant myeloid progeny with normal differentiation activity, which contribute to normal hematopoiesis in remission, giving rise to mature hematopoietic cells that possess a limited lifespan. In this case, the t(8;21) ϩ progenitors themselves should not cause AML. Alternatively, because it has not yet been proven that these t (8;21) ϩ progenitors give rise to mature blood cells in vivo, the residual leukemia clones may be latent in vivo, but differentiate into mature myeloid cells in vitro in response to exogenous cytokines. This is not unlikely because t(8;21) AML usually presents AML-M2 (by French-American-British classification) that is characterized by the differentiating tendency of leukemic blasts (1) .
To clarify the origin of AML1͞ETO transcripts, we surveyed AML1͞ETO mRNA expression in rigorously purified HSC, progenitors, and mature hematopoietic cells of various lineages. Our study demonstrates that acquisition of t(8;21) occurs in progenitors or HSC, that the translocation is a necessary, but not sufficient, precondition for transformation, and that these t(8;21) ϩ progenitors contribute to B lymphopoiesis as well as myelopoiesis throughout the clinical course of t(8;21) AML.
Materials and Methods
Patients. The clinical characteristics of patients are shown in Table  1 . This study included BM mononuclear cells from six cases with t(8;21) AML in leukemic phase (cases 1-4, 5a, and 6a), and 13 cases in remission (cases 5b, 6b, 12, 13, 15-18, 20, and 22-25) . An additional eight patients (cases 7-11, 14, 19, and 21) , whose samples were analyzed only in our previous study (10) and who maintained remission at the time of this report, were entered in this study. Remission was achieved by the protocols at the Hiroshima Red Cross Hospital (11) or in the Fukuoka Bone Marrow Transplantation Group (12) . Six patients (cases 5-10) were further treated with auto-MBT (12) , and the remaining cases received intensification chemotherapy (11) . All patients studied remained in remission at the time of this report. The median remission duration at the time of sampling was 37 and 32 months, and the median disease-free survival was 98 and 97 months in the patient groups treated with chemotherapy and auto-MBT, respectively. Informed consent was obtained from all patients.
Cell Purification by Triple-Sorting by Using a Five-Color Flow Cytometer. BM cells were cryopreserved by using hydroxyethyl starch and DMSO as a cryoprotective agent at Ϫ80°C (13). For sorting HSC and progenitor populations, BM cells were stained with Cy5-phycoerythrin (PE)-conjugated lineage (Lin) mixture (anti-CD3,  -CD4, -CD8, -CD13, -CD16, -CD19, -CD20, -CD33, (16) . The fivecolor sort using both positive and negative gates in multiple channels usually gives rise to cells of more than 98% of purity, avoiding cosorting cells stained in a nonspecific manner. The sorted cells were subjected to two additional rounds of sorting using the same gate to eliminate contaminating cells and doublets (17) . The sample line was washed out by 75% ethanol followed by saline between each round of sorting to eliminate remaining cells.
In Vitro Hematopoietic Progenitor Assay. Clonogenic progenitor assays were performed by using the methylcellulose culture system as reported (10, 15) . Human cytokines such as steel factor (20 ng͞ml), IL-3 (30 ng͞ml), IL-6 (10 ng͞ml), erythropoietin (2 units͞ml) , and thrombopoietin (20 ng͞ml) (R & D Systems) were added at the start of the culture. An automatic cell deposition unit system (Becton Dickinson) (15) was used to deposit single cells onto 96-well plates.
RT-PCR Analysis. Total RNA was extracted from purified cells and colonies by the acid guanidine͞phenol͞chloroform method. The detailed method for RT-PCR and the primer sequences were described elsewhere (9, 10). Each PCR product was confirmed to be the expected sequences by testing the length of fragments after digesting with DNA restriction enzyme ApaI or by Southern blot analysis using the probe spanning the AML1͞ETO junction (10) . A t(8;21) AML cell line, Kasumi-1 (18) , was used as a positive control. The nested RT-PCR assay we used could detect AML1͞ETO as well as myeloperoxidase (MPO) genes in a single Kasumi-1 cell among 10 7 T cell lines (9, 10). When we started sorting from a positive control sample that was a mixture of 90% Kasumi-1 and 10% normal BM cells, AML1͞ETO or MPO mRNA was not detected in Ն100,000 triple-sorted T or B cells, indicating that those triple-sorted cells were free from Kasumi-1 contaminants. Based on these data, all RT-PCR analyses were applied only for triple-sorted populations throughout this study. At the end of each experiment, triplesorted 30,000 T cells from the positive control sample were collected and were verified not to be contaminated with Kasumi-1 cells.
Transformation of Purified B Cells by Epstein-Barr Virus (EBV).
Triplesorted B cells were cultured with supernatant from the EBVproducing cell line (19) . The transformed B cells were cultured for more than 3 months, and the EBV-transformed B cell lines were established.
Results

Analysis of Remission and Leukemic BM in t(8,21) AML for HSC and
Progenitor Cells. In remission BM, a minority of the CD34 ϩ fraction contained Thy-1 ϩ stem cells (20) (Fig. 1A) . The most primitive subset of these stem cells is CD38 -/lo (21) . Another fraction of BM is CD34 Fig. 1 A) ; these cells possess lymphoidrestricted differentiation potential (14) . Primitive HSC (CD34 ) that contain self-renewing leukemic stem cells (22) (Fig. 1B) . The purified HSC, CLP, and primitive leukemic progenitors as well as mature monocytes, B cells, and T cells were subjected to further analyses. Table 4 and in our previous report (10) . (Table 2 ). To identify BM subpopulations that express AML1͞ETO transcripts, 500 HSC, 500 CLP, 500 mature B cells, 500 monocytes, or 5,000 mature T cells from the remission BM of 13 cases were subjected to RT-PCR analysis. AML1͞ETO transcripts were detectable in HSC (in seven of 13 cases studied), CLP (in two of 13 cases studied), monocytes (in all 10 cases studied), and B cells (in 10 of 12 cases studied) ( Table 2 ). The AML1͞ETO ϩ B cell population did not express MPO mRNA, indicating that the sorted B cells were not contaminated with myelomonocytic cells (Fig. 2) . The frequency of AML1͞ETO ϩ cells was estimated at limit dilution, where Poisson statistics would allow determination of the average number of cells that contains a single AML1͞ETO ϩ cell (15) . In this analysis, the frequency of AML1͞ETO ϩ cells was 1 in 3,000-4,800 (median 4,500) monocytes in five cases studied (cases 5b, 6b, 12, 20, and 22), and 1 in 20,000-45,000 (median 36,000) mature B cells in six cases studied (cases 5b, 6b, 20, and 22-24). Typical limit dilution tests in cases 5 and 6 are shown in Fig. 3 . In contrast, in all cases, AML1͞ETO transcripts were undetectable in mature T cells.
AML1͞ETO-Expressing Cells in Leukemic Phase of t(8;21) AML Include
B Cells, but Not T Cells. We analyzed the expression of AML1͞ETO in purified T and B cells from leukemic BM in five cases (cases 1, 3-6) ( Table 3 ). In all 500 pooled CD34 
CD38
-/lo leukemic progenitors, we detected AML1͞ETO transcripts. Strikingly, AML1͞ETO ϩ mature B cells were detectable in all cases and existed at a higher frequency (1 in 5,000 to 6,200 cells) in leukemic phase compared with remission (Fig. 3) . However, mature T cells did not express AML1͞ETO in four cases studied.
We used EBV to transform the sorted B cells in cases 1 and 5a. Among 143 B cell lines established from Ϸ3,345 samples, each containing 1,000 B cells, four EBV-transformed B cell lines were found to express AML1͞ETO (Fig. 2) . Based on these data, AML1͞ETO ϩ B cells are present at the earliest times tested after diagnosis of t(8;21) AML.
AML1͞ETO Is Expressed in Various Myeloid
Colony-Forming Progenitors in Both the Leukemic and the Remission Phases. We analyzed the expression of AML1͞ETO in myeloid colony-forming progenitors in remission BM from five cases (cases 5b, 6b, 15, 16, and 18), in addition to cases reported in our previous study (10) . The plating efficiency of single cell culture of purified HSC in methylcellulose was 53.7%. As shown in Table 4 , a small, but significant, percent of single cell-derived colonies of various myeloid lineages expressed AML1͞ETO in all cases.
We also cultured the CD34 
Each population was purified by a five-color FACS sorting and pooled either 500 cells (HSC, CLP, monocytes, and B cells) or 5,000 cells (T cells) were analyzed by RT-PCR for AML1͞ETO mRNA. Representative data are shown in Fig. 2 A. ND, not done. Table  2 . Note that MPO gene is not expressed in AML1͞ETO ϩ pooled B cells and CLP, which confirms that the samples do not contain myelomonocytic cells. (B) RT-PCR analysis on purified cells from leukemic BM. Representative data in case 5a are shown. All 500 pooled CD34 ϩ CD38 -/lo and CD34 ϩ CD38 ϩ cells expressed AML1͞ETO mRNA, which is detectable by the first round of PCR, and AML1͞ETO ϩ B cells were found at a higher frequency compared with those in remission BM as summarized in Table 3 . The last five right lanes show results of PCR analysis in two AML1͞ETO ϩ and three AML1͞ETO -EBV-transformed B cell lines established from case 1. Note that in these AML1͞ETO ϩ B cell lines, AML1͞ETO transcripts were detectable by the first round of PCR amplification. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Spearman rank correlation analysis; the results shown in Table  1 summarize all of our data here and elsewhere (10) . The frequencies of AML1͞ETO ϩ myeloid progenitors decrease along with remission duration in both patient groups treated with autologous MBT and chemotherapy (Fig. 5) . In 15 patients treated with chemotherapy who had maintained complete remission for more than 5 years after the sampling, the frequency of AML1͞ETO ϩ progenitors and the duration of remission were inversely correlated (P ϭ 0.0006, r ϭ Ϫ0.907).
Discussion
We demonstrate that t(8;21)-specific AML1͞ETO mRNA is expressed in mature monocytes and B cells as well as HSC, lymphoid progenitors, and myeloid progenitors during remission. This strongly suggests that t(8;21) ϩ HSC in remission that are capable of self-renewal differentiate into mature blood cells in vivo.
Fialkow and coworkers (23) (24) (25) reported that hematopoiesis in remission might be supported by HSC that share a clonal origin with AML, given the observation that X-chromosome inactivation patterns of glucose-6-phosphate dehydrogenase gene in colony-forming progenitors, mature granulocytes, and B cells in remission frequently were skewed toward those in AML blasts. The ''clonal remission'' in AML patients suggested that dominant ''preleukemic'' stem cells capable of normal differentiation may exist, and that additional mutational event(s) may transform these preleukemic stem cells into true leukemic stem cells as a result of a multistep leukemogenesis (26, 27) . On the other hand, remission hematopoiesis in t(8;21) AML determined by conventional X-chromosome inactivation analyses is usually polyclonal (10, 28) . We have shown that, although a major population of AML1͞ETO -myeloid progenitors in remission inactivated either allele of the X-chromosome-linked phosphoglycerate kinase (PGK) gene, t(8;21) AML blasts and AML1͞ETO ϩ myeloid progenitors in remission are of clonal origin because both inactivated the identical allele of PGK gene (10) . We demonstrate here that t(8;21) could occur at a stem cell level as a primary event of leukemogenesis. Because the percentages of AML1͞ETO-expressing myeloid progenitors and B cells in leukemic phase were significantly higher than those in remission, the t(8;21) ϩ HSC might be dominant before or at the onset of t(8;21) AML. After treatment, the t(8;21) ϩ HSC become a minor population, and their frequency gradually declined in remission. These data strongly suggest that additional oncogenic event(s) might be required for the t(8;21) ϩ HSC to become t(8;21) ϩ leukemic stem cells. FACS-purified 288 single CD34 ϩ Thy-1 ϩ CD38 Ϫ͞lo cells in remission marrow and 1,440 CD34 ϩ Thy-1 Ϫ CD38 Ϫ͞lo cells in leukemic marrow were cultured in methylcellulose, and all colonies formed were picked on day 14 for RT-PCR analysis. Representative data are shown in Fig. 4 . Note that erythrocyte and megakaryocyte colonies did not express MPO gene, which confirms that these colonies did not contain myelomonocytic components. The frequency of these AML1͞ETO ϩ myeloid progenitors was up to 60% in total myeloid colonies as shown in Table 4 . GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
To interpret ''residual diseases'' at a molecular level, both the specificity and the sensitivity of assays are important. The residual BCR͞ABL in chronic myelogenous leukemia and PML͞RAR␣ in t (15, 17) AML occasionally become undetectable in patients maintaining remission, but this does not necessarily indicate their permanent cure (29, 30) . In childhood acute lymphoblastic leukemia, persistence of leukemia-specific T cell antigen receptor rearrangements in long-term remission have been reported (31) . Our study shows that t(8;21)-specific AML1͞ETO does not necessarily mark leukemic cells. Therefore, it is important to know whether the residual cells found in various hematological malignancies are progeny of malignant or nonmalignant stem cells with leukemiaspecific genes.
This study also provides quantitative information of residual cells in t(8;21) AML remission; the residual AML1͞ETO ϩ cells originate from a small number of t(8;21) ϩ HSC, and these decline along with remission duration in patients who had been clinically cured. The gradual fade-out of t(8;21) ϩ HSC could be caused by host immune surveillance during remission or natural productive lifespan of these clones. Thus, eradication of acute leukemia clones, but not of t (8;21) ϩ HSC might be required to cure t(8;21) AML patients.
It is of interest that AML1͞ETO mRNA was undetectable in T cells throughout the patients' clinical course, and the frequency of AML1͞ETO ϩ cells in B cells was estimated to be Ϸ10-fold less than that in monocytes. Although it is necessary to confirm the absence of AML1͞ETO chimeric DNA in T cells, AML1͞ETO may inhibit lymphoid rather than myeloid differentiation (32) . Interestingly, cell populations involved in BCR͞ABL are similar in chronic myelogenous leukemia patients; BCR͞ABL is detectable in all myeloid cells, Ϸ20% of the mature B cell (33) , and rarely in T cells (34 -36) . It is possible that in normal adults, the demands for lymphoid (especially T cell) regeneration of these long-lived cells may be rare, compared with regeneration of short-lived myeloid cells.
Thus, the formation and expression of the AML1͞ETO chimeric gene is not sufficient for leukemic transformation in t(8;21) AML. The AML1͞ETO fusion protein may play an important and early step in the process that can lead to leukemic transformation, possibly through suppressing normal AML1 function in a dominant negative manner (37, 38) to cause myelodysplasia (38) or through inhibiting apoptotic cell death of hematopoietic progenitors (39, 40) . Although t(8;21) ϩ HSC are not leukemic, some of their downstream progeny might achieve additional mutation(s) to become dominant before leukemic transformation and to expand to obliterate the niches that support both normal HSC and lymphoid progenitors. Furthermore, because virtually all leukemias with t(8;21) exhibit AML, these additional mutational events might preferentially involve differentiation machinery of the myeloid lineage. Further investigations on the function of the AML1͞ETO fusion protein and on additional gene alterations in t(8;21) ϩ HSC or progenitors are required to understand the cooperative mechanisms among multiple oncogenic events that ultimately lead to the occurrence of t(8;21) AML. 5 . Gradual decrease in frequency of AML1͞ETO ϩ progenitors along with remission duration. Twenty-one remission marrow samples from 19 patients who had maintained complete remission Ͼ5 years after the sampling were analyzed. Fifteen cases were treated with chemotherapy (F) and four cases were treated with autologous MBT (E). The frequency of AML1͞ETO ϩ myeloid progenitors and remission duration at the time of sampling appeared to be inversely correlated by a Spearman rank correlation analysis (P ϭ 0.0006, r ϭ Ϫ0.907 in patients treated with chemotherapy; P ϭ 0.2774, r ϭ Ϫ0.486 in patients treated with autologous MBT; P ϭ 0.0007, r ϭ Ϫ0.751 in total patients). The correlation curve shows the result in patients treated with chemotherapy.
